Drug Profile
Giredestrant - Genentech
Alternative Names: GDC-9545; RG-6171; RO-7197597Latest Information Update: 20 Feb 2024
Price :
$50
*
At a glance
- Originator Genentech
- Developer Chugai Pharmaceutical; Genentech; Roche
- Class 3-ring heterocyclic compounds; Amines; Antineoplastics; Azetidines; Fluorobenzenes; Indoles; Piperidines; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- Phase II Endometrial cancer
- Phase I Solid tumours
Most Recent Events
- 16 Feb 2024 MedSIR plans a phase II trial for Breast cancer (Monotherapy, Combination therapy; Adjuvant therapy) in (PO) in 1st March 2024 (NCT05708235) (EudraCT2022-002616-24)
- 14 Feb 2024 Fondazione Oncotech plans a phase II Neo-AGILE trial for HER2 negative breast cancer (Neoadjuvant therapy, First line therapy) in Italy (PO), in April 2024
- 23 Jan 2024 Phase-II clinical trials in HER2-negative-breast-cancer (Combination therapy, Early-stage disease) in Switzerland, Sweden, Spain, Italy, Ireland, Hungary, Germany, France (PO) (NCT05896566)